Sanofi’s Wayrilz Approved in US as First BTK Inhibitor for Immune Thrombocytopenia
The U.S. Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor, for adults with persistent or chronic immune…
Read More...
Read More...
